Page last updated: 2024-12-08
1-deoxycastanospermine
Description
## 1-Deoxycastanospermine: A Sugar Mimic with Potential
1-Deoxycastanospermine (1-DC) is a natural product derived from the Australian native plant, **Castanospermum australe**, commonly known as the **Moreton Bay Chestnut**. It belongs to a family of compounds called **polyhydroxylated alkaloids**, characterized by their complex sugar-like structure.
### Why is 1-Deoxycastanospermine important for research?
1-DC is particularly interesting due to its potent ability to **inhibit specific enzymes involved in carbohydrate metabolism**. Specifically, it acts as a **competitive inhibitor** of **α-glucosidase and α-mannosidase enzymes**. These enzymes are critical for breaking down complex carbohydrates, like starch and glycoproteins, into simpler sugars that can be absorbed by the body.
This inhibitory activity has led to significant research interest in 1-DC for various applications:
**1. Diabetes Treatment:**
* By inhibiting α-glucosidase, 1-DC can delay the absorption of glucose from the gut, leading to a slower rise in blood sugar levels after meals. This makes it a potential therapeutic agent for **Type 2 Diabetes**.
**2. Cancer Research:**
* 1-DC has shown **anti-tumor activity** in several studies, potentially by interfering with the glycosylation of cancer cells, a process crucial for their survival and proliferation.
**3. Viral Infections:**
* Some viruses, like HIV, rely on glycosylation for their attachment to host cells. 1-DC's inhibition of glycosidases can potentially hinder viral infection and replication.
**4. Other Applications:**
* 1-DC's ability to interfere with glycosylation has also been explored for applications in **anti-inflammatory treatments**, **neurodegenerative diseases**, and **immunomodulation**.
### Ongoing Research:
Despite its promising potential, research on 1-DC is still ongoing. Key challenges include:
* **Toxicity**: While 1-DC shows therapeutic potential, it also exhibits some toxicity. Researchers are working on developing safer and more effective derivatives.
* **Pharmacokinetic Properties**: Understanding the absorption, distribution, metabolism, and excretion of 1-DC in the body is crucial for developing effective therapeutic strategies.
* **Clinical Trials**: While preclinical studies have shown promising results, more extensive clinical trials are needed to validate 1-DC's safety and efficacy for various medical applications.
**Overall, 1-Deoxycastanospermine represents a fascinating molecule with potential applications in various medical fields. Ongoing research aims to unlock its therapeutic potential while addressing its limitations, ultimately leading to novel treatments for diverse health conditions.**
1-deoxycastanospermine: indolizidine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 195154 |
MeSH ID | M0181024 |
Synonyms (12)
Synonym |
1-deoxycastanospermine |
115649-93-9 |
(6s,7r,8r,8ar)-1,2,3,5,6,7,8,8a-octahydroindolizine-6,7,8-triol |
1-deoxy-6,8a-diepicastanospermine |
6,7,8-trihydroxyindolizidine |
1-deoxy-6-epicastanospermine |
1-deoxy-8a-epi-castanospermine |
6,7,8-trihydroxy-indolizidine |
1-deoxy-castanospermine |
6,7,8-indolizinetriol, octahydro-, (6s-(6alpha,7beta,8alpha,8aalpha))- |
octahydroindolizine-6,7,8-triol |
DTXSID00921781 |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.56 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.51 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |